Research programme: prostate cancer antibodies - Immunex

Drug Profile

Research programme: prostate cancer antibodies - Immunex

Alternative Names: Prostate cancer antibody research programme - Immunex

Latest Information Update: 29 Jul 2002

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator UroCor
  • Developer Amgen; UroCor
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Prostate cancer

Most Recent Events

  • 29 Jul 2002 Immunex was acquired by, and merged into, Amgen.
  • 11 Jul 2000 New profile
  • 11 Jul 2000 Preclinical development for Prostate cancer in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top